Postępy w leczeniu przeciwzakrzepowym Artykuł przeglądowy

##plugins.themes.bootstrap3.article.main##

Anna Kaczyńska

Abstrakt

Idealny antykoagulant powinien być lekiem doustnym, powinien nie wymagać rutynowego monitorowania efektu przeciwzakrzepowego, mieć szerokie okno terapeutyczne i przewidywalną zależność dawka-odpowiedź, nie wykazywać interakcji z innymi lekami i z pokarmami oraz mieć mało działań niepożądanych. Ostatnio dwa nowe antykoagulanty zostały zaakceptowane w leczeniu, a kolejne są w fazie badań klinicznych.

Pobrania

Dane pobrania nie są jeszcze dostepne

##plugins.themes.bootstrap3.article.details##

Jak cytować
Kaczyńska , A. (2010). Postępy w leczeniu przeciwzakrzepowym . Kardiologia W Praktyce, 4(4), 154-161. Pobrano z https://journalsmededu.pl/index.php/kwp/article/view/1627
Dział
Artykuły

Bibliografia

1. Guidelines for the management of atrial fibrillation. Eur. Heart J. 2010, 31: 2369-2924.
2. DeCaterina R., Husted S. Wallentin L. et al.: Anticoagulants in heart disease: current status and perspectives. Eur. Heart J. 2007, 28: 880-913.
3. Viskov C., Just M., Laux V. et al.: Description of the chemical and pharmacological characteristics of a new hemisynthetic ultra-low-molecular heparin, AVE5026. J. Thromb. Haemost. 2009, 7(7): 1143-1151.
4. Lassen M.R., Dahl O.E., Mismetti P. et al.: AVE5026, a new hemistnthetic ultra-low-molecular-weight heparin for the prevention of venous thromboembolism in patients after total knee replacement surgery – TREK: a dose ranging study. J. Thromb. Haemost. 2009, 7(4): 566-572.
5. Zhang Z.G., Zhang Q.Z., Cheng Y.N. et al.: Antagonistic effects of ultra-low-molecular-weight-heparin against cerebral ischemia/reperfusion injury in rats. Pharmacol. Res. 2007, 56(4): 350-355.
6. Wittowsky A.: New oral anticoagulants: a practical guide for clinicians. J. Thromb. Thrombolysis 2009, 29: 182-191.
7. Friedman R.J., Dahl O.E., Rosencher N. et al.; RE-MOBILIZE RE-MODEL RE-NOVATE steering committee. Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials. Thromb. Res. 2010, 126(3): 175-182.
8. Connoly S.J., Yusuf S., Eikelboom J. et al.; RE-LY steering committee and investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 2009, 361(12): 1139-1151.
9. Schulman S., Kearon C., Kakkar A.K. et al.; RE-COVER study group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N. Engl. J. Med. 2009, 361(24): 2342-2352.
10. Becattini C., Lignani A., Agnelli G.: New anticoagulants for the prevention of venous thromboembolism. Drug Design, Development and Therapy 2010, 4: 49-60.
11. ROCKET study investigators. Rivaroxaban – once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation: rationale and design of the ROCKET AF study. Am. Heart J. 2010, 159(3): 340-347.
12. Lassen M.R., Raskob G.E. Gallus A. et al.; ADVANCE-2 investigators. Apixaban versus enoxaparin for thromboprophylaxis after knee repacement (ADVANCE-2). Lancet 2010, 375: 807-815.
13. Lopes R.D., Alexander J.H., Al-Khatib S.M. et al.; ARISTOTLE investigators. Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am. Heart J. 2010, 159(3): 331-339.
14. Linkins L., Weitz J.: New and emerging anticoagulant therapies for venous thromboembolism. Current Treatment Options in Cardiovascular Medicine 2010, 12: 142-155.
15. van Ryn J., Stangier J., Haertter S.: Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb. Haemost. 2010, 103: 1116-1127.
16. Harder S., Parisius J., Picard-Willems B.: Monitoring direct FXa-inhibitors and fondaparinux by prothrombinase-induced clotting time. Thromb. Res. 2008, 123: 396-403.
17. Crowther M.A., Berry L.R., Monagle P.T., Chan A.K.: Mechanisms responsible for the failure of protamine to inactivate low-molecular-weight-heparin. Br. J. Haematol. 2002, 116(1): 178-186.
18. Godier A., Durand M., Emmerich J. et al.: Efficacy of prothrombin complex concentrate to reverse the anticoagulant effect of the pentasaccharide fondaparinux in rabbit model. Thromb. Haemost. 2010, 105(1) [online].
19. Bianchini E.P., Fazavana J., Picard V., Borgel D.: Development of a recombinant antithrombin variant as a potent antidote to fondaparinux and other heparin deriveratives. Blood 2010 [online].
20. Paty I., Trellu M., Destors J.M. et al.: Reversability of the anti-FXa activity of idrabiotaparinux by intravenous avidin infusion. J. Thromb. Haemost. 2010, 8(4): 722-729.